Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen
Chronic lymphocytic leukaemia that develops in patients with rare germline ATM variants is more likely to have 11q deletion
It is a generic of Mozobil which has been authorised in the EU since 2009
Findings from the DREAMseq study
PembroRad shows less toxicity from standard of care regimen in unfit patients
Impact of NGS-based detection of FLT3 internal tandem duplication measurable residual disease on treatment outcome in newly diagnosed acute myeloid leukaemia
Evidence for efficacy is based on the results from the MajesTEC-1 study
It is a generic of Alimta which has been authorised in the EU since 2004
Rate of systemic anticancer treatment use within 30 days of death across all cancer types did not change in recent years
5-year outcomes with pembrolizumab versus chemotherapy in the KEYNOTE-042 study
Findings from the IARC working group review of all relevant published studies
Evidence for efficacy is based on the results from the HIMALAYA study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
